Skip to content
glp1.howSign in

Zepbound

Eli Lilly's brand name for injectable tirzepatide, FDA-approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity.

Updated Sep 26, 2026

Zepbound is the brand name for injectable tirzepatide manufactured by Eli Lilly. The FDA approved it in November 2023 for chronic weight management in adults with obesity or overweight plus a related condition (FDA (external link)). It shares its active ingredient with Mounjaro, which is approved for type 2 diabetes.

It also carries a second indication: moderate-to-severe obstructive sleep apnea in adults with obesity. The FDA's December 2024 approval made it the first medication approved to treat sleep apnea itself, and not only the weight behind it (FDA (external link)). That approval followed the phase 3 SURMOUNT-OSA trials, in which tirzepatide reduced the apnea-hypopnea index, hypoxic burden, and body weight (Beccuti et al., Current Obesity Reports, 2024, DOI (external link)). See our guide on sleep quality on a GLP-1.

Was this helpful?

Evidence: For & Against

Both sides of the topic, so you can weigh the evidence yourself.

2Supporting

Revision history

Last updated · 2 revisions recorded.

Show what changed
  1. v2

    Body revised

  2. v1

    Existing article recorded at the start of version history

Improve this page

Community notes

Share helpful experiences and questions. Notes are reviewed before publication and do not replace medical advice.

Loading notes…

    New submissions are currently paused. Existing approved notes remain available.

    Related terms

    • Hazard ratio — A statistic from clinical trials that compares how often an event happens over time in one group versus another; below 1 means a lower rate in the treated group.
    • Sharps container — A puncture-resistant container for safely collecting used needles, pen needles, and syringes until they can be disposed of according to local rules.
    • Oral semaglutide — Semaglutide taken as a once-daily pill instead of a weekly injection: Rybelsus and its reformulation, Ozempic tablets, for type 2 diabetes, and the Wegovy pill for weight management.

    Related guides

    • Gastric emptying on a GLP-1: how much slower, how long it lasts, and what it means for gastroparesis — GLP-1 medications slow the stomach, but the trials show the effect is smaller and fades more than most people assume, especially with the long-acting weekly drugs. This guide covers how much slower, whether it lasts, how gastric emptying is measured, how it differs from gastroparesis, and why the "food ferments in your stomach" claim has no evidence behind it.
    • Restarting a GLP-1 after a missed stretch: what each drug's label says about re-titration — Missed a few weeks of Wegovy, Zepbound, Ozempic, Trulicity, Saxenda, or a GLP-1 pill? Only four labels spell out when to restart at a lower dose: Wegovy injection after 2 missed weekly doses, Saxenda and Victoza after more than 3 days, and Foundayo after 7 missed daily doses. The rest are silent on long gaps. This by-drug reference separates what each label says from what's left to your prescriber, and explains why going straight back to your old dose is risky.
    • Comparing the GLP-1 pills: Ozempic tablets (Rybelsus), the Wegovy pill, and Foundayo — There are now three GLP-1 pills in the US, and they aren't interchangeable: oral semaglutide for diabetes (Rybelsus, now sold as Ozempic tablets), oral semaglutide for weight (the Wegovy pill), and orforglipron (Foundayo). Here's how they compare on approval, how you take them, what the trials found, side effects, cost, and what you give up versus a weekly injection.